Fort Washington Investment Advisors Inc. OH Has $47.40 Million Stock Position in Haemonetics Corporation $HAE

Fort Washington Investment Advisors Inc. OH raised its position in Haemonetics Corporation (NYSE:HAE) by 17.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 841,017 shares of the medical instruments supplier’s stock after purchasing an additional 124,020 shares during the quarter. Fort Washington Investment Advisors Inc. OH owned approximately 1.81% of Haemonetics worth $47,400,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. AQR Capital Management LLC lifted its holdings in shares of Haemonetics by 372.8% during the 3rd quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock valued at $102,814,000 after buying an additional 1,678,630 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Haemonetics by 994.7% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier’s stock worth $110,615,000 after buying an additional 1,254,035 shares during the last quarter. Millennium Management LLC raised its position in Haemonetics by 4,296.3% during the third quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock valued at $37,685,000 after acquiring an additional 755,592 shares in the last quarter. North Peak Capital Management LLC lifted its stake in Haemonetics by 204.4% in the fourth quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier’s stock valued at $88,405,000 after acquiring an additional 740,626 shares during the last quarter. Finally, Invenomic Capital Management LP lifted its stake in Haemonetics by 1,691.5% in the third quarter. Invenomic Capital Management LP now owns 498,317 shares of the medical instruments supplier’s stock valued at $24,288,000 after acquiring an additional 470,502 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Stock Performance

Shares of HAE opened at $77.34 on Friday. The company has a market capitalization of $3.51 billion, a PE ratio of 38.29, a price-to-earnings-growth ratio of 1.56 and a beta of 0.56. Haemonetics Corporation has a one year low of $47.31 and a one year high of $87.32. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.95 and a quick ratio of 1.87. The company’s fifty day moving average price is $65.41 and its 200 day moving average price is $66.87.

Haemonetics (NYSE:HAE) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The firm had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. During the same quarter last year, the firm posted $1.24 EPS. The company’s revenue was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, analysts expect that Haemonetics Corporation will post 5.22 earnings per share for the current year.

Analyst Ratings Changes

HAE has been the topic of several analyst reports. JPMorgan Chase & Co. dropped their price target on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. Robert W. Baird set a $67.00 price objective on shares of Haemonetics in a research note on Friday, May 8th. Mizuho upped their price objective on shares of Haemonetics from $70.00 to $85.00 and gave the stock an “outperform” rating in a report on Monday, June 15th. Weiss Ratings raised shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday. Finally, BTIG Research restated a “buy” rating and set a $84.00 target price on shares of Haemonetics in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $78.33.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.